News
![](/wp/wp-content/themes/gaia/common/images/page_bg_01.png)
![](/wp/wp-content/themes/gaia/common/images/page_bg_02.png)
![](/wp/wp-content/themes/gaia/common/images/page_bg_03.png)
![](/wp/wp-content/themes/gaia/common/images/page_bg_04.png)
![](/wp/wp-content/themes/gaia/common/images/page_bg_05.png)
![](/wp/wp-content/themes/gaia/common/images/page_bg_06.png)
News
Back
Our President & CEO Kazu Kuramori was at the Innate Killer Summit 2019 – Title:GAIA-102 as an NK Cell-Based “Upward Compatible” Modality Over CAR-T-Cell Therapy –
Our President & CEO Kazu Kuramori was at the Innate Killer Summit 2019
– Title:GAIA-102 as an NK Cell-Based “Upward Compatible” Modality Over CAR-T-Cell Therapy –
Themes
- GAIA-102 is a novel immature phenotype of NK cells with a massive killing activity against various types of malignancies
- GAIA-102 eliminates spheroid-forming tumors, which are highly resistant to CAR-T cells
- GAIA-102 is a promising candidate for adoptive immunotherapy of solid tumors as an “upward compatible” modality over CAR-T-cell therapy